First-in-Human experience with LJN452, an orally available non-bile acid FXR agonist, demonstrates potent activation of FXR in healthy subjects

被引：0
|
作者：
Badman, Michael K. [1 ]
Desai, Sachin [1 ]
Laffitte, Bryan [2 ]
Decristofaro, Marc [1 ]
Lin, TsuHan [1 ]
Chen, Jin [1 ]
Reilly, John F. [1 ]
Klickstein, Lloyd [1 ]
机构：
[1] Novartis Inst BioMed Res, Cambridge, MA USA
[2] Novartis Res Fdn, Genom Inst, San Diego, CA USA
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
32
引用
收藏
页码：16A / 17A
页数：2
相关论文
共 8 条
  • [1] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
    Badman, Michael K.
    Chen, Jin
    Desai, Sachin
    Vaidya, Soniya
    Neelakantham, Srikanth
    Zhang, Jie
    Gan, Lu
    Danis, Kate
    Laffitte, Bryan
    Klickstein, Lloyd B.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (03): : 395 - 410
  • [2] Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
    Tully, David C.
    Rucker, Paul V.
    Chianelli, Donatella
    Williams, Jennifer
    Vidal, Agnes
    Alper, Phil B.
    Mutnick, Daniel
    Bursulaya, Badry
    Schmeits, James
    Wu, Xiangdong
    Bao, Dingjiu
    Zoll, Jocelyn
    Kim, Young
    Groessl, Todd
    McNamara, Peter
    Seidel, H. Martin
    Molteni, Valentina
    Liu, Bo
    Phimister, Andrew
    Joseph, Sean B.
    Laffitte, Bryan
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (24) : 9960 - 9973
  • [3] Efficacy of MET409, a potent, novel non-bile acid FXR agonist, in rodents and cynomolgus monkeys
    Wagner, Brandee
    Govek, Steve
    Nagasawa, Johnny
    Douglas, Karensa
    Dedman, Harry
    Milik, Angelica
    Lee, Kyoung-Jin
    Ortiz, Alvaro
    Qian, Jing
    Lu, Nhin
    Bischoff, Eric
    Song, Ken
    Smith, Nicholas
    HEPATOLOGY, 2017, 66 : 1049A - 1049A
  • [4] SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF HPG1860, A NOVEL NON-BILE ACID FXR AGONIST, IN HEALTHY VOLUNTEERS
    Liu, Que
    Cao, Minjun
    DePetrillo, Paolo
    Xu, Xiaodong
    HEPATOLOGY, 2021, 74 : 1123A - 1123A
  • [5] MET409, a Potent, Non-Bile Acid Sustained FXR Agonist, Shows Rapid Disease Reversal in a Diet-Induced Obese Mouse Model of Biopsy-Confirmed Nash
    Wagner, Brandee
    Govek, Steve
    Nagasawa, Johnny
    Douglas, Karensa
    Dedman, Harty
    Milik, Angelica
    Lee, Kyoung-Jin
    Ortiz, Alvaro
    Qian, Jing
    Lu, Nhin
    Liu, Xueqing
    Bischoff, Eric
    Voldem-Clausen, Kristoffer
    Veidal, Sanne
    Feigh, Michael
    Song, Ken
    Smith, Nick
    HEPATOLOGY, 2018, 68 : 1006A - 1006A
  • [6] First-in-Human study of LMB763, a novel, orally-available farnesoid X receptor agonist that demonstrates modulation of the pharmacodynamic markers FGF19 and C4 in healthy subjects
    Huttner, K.
    Desai, S.
    DeCristofaro, M.
    Laffitte, B.
    Lin, T.
    Chen, J.
    Klickstein, L.
    Badman, M. K.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S425 - S425
  • [7] ID119031166, A NOVEL POTENT NON-BILE ACID FXR AGONIST, IMPROVES NASH AND LIVER FIBROSIS WITHOUT PLASMA LDL- C ELEVATION IN A DIET-INDUCED OBESE NASH HAMSTER MODEL
    Moon, An-Na
    Lee, Yoonsuk
    Song, Dong--Keun
    Briand, Francois
    HEPATOLOGY, 2022, 76 : S611 - S611
  • [8] MET409, a potent, non-bile acid sustained FXR agonist, improves NAFLD activity score and exerts anti-fibrotic effects in a diet-induced obese mouse model of biopsy-confirmed fibrosing NASH
    Veidal, Sanne
    Feigh, Michael
    Tolbol, Kirstine
    Smith, Nicholas
    Wagner, Brandee
    JOURNAL OF HEPATOLOGY, 2020, 73 : S682 - S683
1